Andelen af patienter med mindst én SRE (eksklusiv hypercalcæmi) var 29, 8% i den Zometa behandlede gruppe sammenlignet med 49, 6% i placebo gruppen (p=0, 003).
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8% in the Zometa-treated group versus 49.6% in the placebo group (p=0.003).